Back to top
more

TELA Bio (TELA)

(Delayed Data from NSDQ)

$1.94 USD

1.94
11,329

+0.08 (4.30%)

Updated Aug 4, 2025 01:53 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

NeoGenomics (NEO) Meets Q2 Earnings Estimates

by Zacks Equity Research

NeoGenomics (NEO) delivered earnings and revenue surprises of 0.00% and -0.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

TELA Bio (TELA) delivered earnings and revenue surprises of -19.05% and 6.13%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

TELA Bio (TELA) delivered earnings and revenue surprises of 0% and 24.25%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Caribou Biosciences (CRBU) delivered earnings and revenue surprises of 2.50% and 18.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q3 Loss, Lags Revenue Estimates

by Zacks Equity Research

TELA Bio (TELA) delivered earnings and revenue surprises of -13.51% and 0.75%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zai Lab Limited (ZLAB) Surges 11.1%: Is This an Indication of Further Gains?

by Zacks Equity Research

Zai Lab Limited (ZLAB) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

TELA Bio (TELA) delivered earnings and revenue surprises of -13.33% and 15.31%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Artivion (AORT) Surpasses Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Artivion (AORT) delivered earnings and revenue surprises of 133.33% and 0.33%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Vertex Pharmaceuticals (VRTX) Q1 Earnings and Revenues Top Estimates

by Zacks Equity Research

Vertex (VRTX) delivered earnings and revenue surprises of 16.10% and 5.15%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

The Joint Corp. (JYNT) Beats Q1 Earnings and Revenue Estimates

by Zacks Equity Research

The Joint (JYNT) delivered earnings and revenue surprises of 300% and 1.91%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Syros Pharmaceuticals (SYRS) Soars 22.2%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Syros Pharmaceuticals (SYRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

TELA Bio (TELA) delivered earnings and revenue surprises of -20.45% and 2.09%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AnaptysBio, Inc. (ANAB) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

AnaptysBio, Inc. (ANAB) delivered earnings and revenue surprises of 8.62% and 174.29%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

Werewolf Therapeutics, Inc. (HOWL) delivered earnings and revenue surprises of 23.26% and 45.42%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Wave Life Sciences (WVE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 20.69% and 0.73%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

AbCellera Biologics Inc. (ABCL) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of 15.38% and 21.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Roivant Sciences Ltd. (ROIV) Surges 8.9%: Is This an Indication of Further Gains?

by Zacks Equity Research

Roivant Sciences Ltd. (ROIV) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Zacks Equity Research

Strength Seen in TELA Bio, Inc. (TELA): Can Its 11.4% Jump Turn into More Strength?

by Zacks Equity Research

TELA Bio, Inc. (TELA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -23.53% and 2.39%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

SmileDirectClub (SDC) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

SmileDirectClub (SDC) delivered earnings and revenue surprises of -14.29% and 9.61%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q4 Loss, Lags Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of 10.34% and 12.62%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sarepta Therapeutics (SRPT) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sarepta Therapeutics (SRPT) delivered earnings and revenue surprises of 3.12% and 3.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TELA Bio, Inc. (TELA) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

TELA Bio, Inc. (TELA) delivered earnings and revenue surprises of -12.28% and 4.78%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sutro Biopharma, Inc. (STRO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -146.67% and 121.56%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?